Key result
Nucleic acids show potential as alternative therapeutics and nanocarriers for rheumatoid arthritis.
Why the study?
Current rheumatoid arthritis therapies mainly alleviate progression or pain, and emerging biological DMARDs require long-term treatment, prompting the exploration of nucleic acids as alternative therapeutics or nanocarriers.
Nucleic acids, including therapeutic RNAs, aptamers, and DNA nanostructures, represent a promising alternative approach for the diagnosis and treatment of rheumatoid arthritis.
Answers are grounded in this paper and cite their sources.
Nucleic acid nanotherapies remain investigational in RA; leaves open their clinical role pending randomized trials.
Rheumatoid arthritis (RA) is a common systemic inflammatory autoimmune disease that severely affects the life quality of patients. Current therapeutics in clinic mainly focus on alleviating the development of RA or relieving the pain of patients. The emerging biological disease-modifying antirheumatic drugs (DMARDs) require long-term treatment to achieve the expected efficacy. With the development of bionanotechnology, nucleic acids fulfill characters as therapeutics or nanocarriers and can therefore be alternatives to combat RA. This review summarizes the therapeutic RNAs developed through RNA interference (RNAi), nucleic acid aptamers, DNA nanostructures-based drug delivery systems, and nucleic acid vaccines for the applications in RA therapy and diagnosis. Furthermore, prospects of nucleic acids for RA therapy are intensively discussed as well.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2022) conducted a review in Rheumatoid arthritis. Nucleic acids (therapeutic RNAs, aptamers, DNA nanostructures, nucleic acid vaccines) was evaluated. Nucleic acids, including therapeutic RNAs, aptamers, DNA nanostructures, and nucleic acid vaccines, show potential as alternative therapeutics and nanocarriers for rheumatoid arthritis treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: